Plus Therapeutics (NASDAQ:PSTV) is a clinical-stage pharmaceutical company focused on the development of innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers. Their work centers around harnessing the power of radiation therapy in new, minimally invasive ways to provide better treatment options for patients with cancer. Plus Therapeutics is actively advancing a portfolio of promising drug candidates through clinical trials, aiming to address the unmet medical needs of patients suffering from cancers that currently have limited treatment options. Their objective is to significantly improve outcomes and the quality of life for cancer patients by bringing breakthrough therapies to market.